Clinical Trials Sponsored by Nordic Pharma, USA

Total 373 results

Nordic Pharma, USA
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Completed

Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.

Triglycerides | LDL Cholesterol

Canada
Nordic Pharma, USA
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Completed

A Comparator Trial on the Relative Efficacy of Two Triglyceride Forms of Fish Oil

Healthy Volunteers

Canada
Nordic Pharma, USA
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Withdrawn

Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction (PrOteCT)

Mixed Hyperlipoproteinemia
Nordic Pharma, USA
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Completed

A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products

Comparative Bioavailability

Canada
Chugai Pharma USA

Completed

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

Gastroparesis

United States
Chugai Pharma USA

Completed

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

Atherosclerosis | Coronary Restenosis | Graft Occlusion, Vascular

United States
Chugai Pharma USA

Completed

An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer

Breast Cancer | Breast Neoplasms | Metastasis

United States
Nordic Pharma SAS

Active, not recruiting

Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis (STRATEGE2)

Rheumatoid Arthritis | Psoriatic Arthritis

France
Nordic Pharma SAS

Completed

Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis (APRim)

Rheumatoid Arthritis

France
Nordic Pharma SAS

Completed

Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe (Self-i)

Arthritis, Rheumatoid

France
Nordic Pharma SAS

Completed

Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea

Medical Termination of Pregnancy

France
Nordic Pharma SAS

Completed

Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis (STRATEGE)

Rheumatoid Arthritis

France
Nordic Pharma SAS

Completed

Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion

Abortion; Attempted, Medical

France
Nordic Pharma SAS

Unknown

Prevention of Adhesions During Celioscopy for Endometriosis. Impact of the Use of Anti-adhesion Treatment on Clinical Signs and Fertility at One Year (ENDHY)

Endometriosis, Adhesive

France
Nordic Pharma SAS

Completed

Spinal Versus General Anesthesia for Ambulatory Anesthesia (BAG)

Spinal Anesthesia | Outpatient Surgery | Short General Anesthesia

France
Nordic Pharma SAS

Terminated

Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (SPARROW)

Wegeners Granulomatosis

Czech Republic
Nordic Pharma SAS

Completed

Impact of Chloroprocaine (CLOROTEKAL®) on Eligibility for Discharge From Hospital After Outpatient Surgery (CLOCK)

Spinal Anesthesia | Outpatient Surgery

France
Teikoku Pharma USA, Inc.

Recruiting

Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty (DMT2111)

Pain, Postoperative

United States
Meiji Pharma USA Inc.

Completed

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States, Canada
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Teikoku Pharma USA, Inc.

Unknown

Evaluating Efficacy of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty

Pain, Postoperative

United States
Fidia Pharma USA Inc.

Completed

2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)

Knee Osteoarthritis | Osteoarthritis, Knee | Patellofemoral Osteoarthritis

United States
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
Horizon Pharma USA, Inc.

Completed

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
Horizon Pharma USA, Inc.

Recruiting

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Thyroid Eye Disease

United States
Teikoku Pharma USA, Inc.

Completed

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System (DTP-System)

Irritation/Irritant

United States
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Horizon Pharma USA, Inc.

Completed

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Cystic Fibrosis (CF)

Germany, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (MITO-001)

Inherited Mitochondrial Disease, Including Leigh Syndrome

United States
Teikoku Pharma USA, Inc.

Completed

Flurbiprofen Tape for Treatment of Chronic Low Back Pain (LBP)

Chronic Low Back Pain

United States
Teikoku Pharma USA, Inc.

Completed

Study of a New Dressing for Use With Topical Medications

Psoriasis

United States
Teikoku Pharma USA, Inc.

Not yet recruiting

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

Agitation
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

United States
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Horizon Therapeutics USA, Inc.

Terminated

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis

United States
Astellas Pharma Inc
Ono Pharma USA Inc

Completed

A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

Bone Diseases | Osteoporosis | Osteoporosis, Postmenopausal

Japan
Horizon Therapeutics USA, Inc.

Completed

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Thyroid Eye Disease | Chronic (Inactive) Thyroid Eye Disease

United States
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Liposarcoma, Dedifferentiated

United States
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel

3

Subscribe